Early experience with the Edwards SAPIEN M3 System, a novel treatment of mitral regurgitation (MR), is “encouraging,” said John Webb, MD, director of interventional cardiology at St. Paul’s Hospital in Vancouver, British Columbia. Webb presented his findings Monday at the Cardiovascular Research Technologies (CRT) 2018 at the Omni Shoreham Hotel in Washington, D.C. Those findings showed that 10 patients treated with SAPIEN M3: were hemodynamically stable throughout the procedure; all had the device successfully implanted; and none was observed to have left ventricular outflow tract obstruction (LVOTO). Also, procedure time and outcomes improved with operator experience, and no mortality was observed at 30 days, the findings by Webb and colleagues showed. Webb said that patients were hemodynamically stable throughout the procedure is “much different than most transapical procedures.” There was no LVOTO, he added, “because the anterior mitral valve leaflets are pulled together by the dock system.” And the lack of mortality at 30 days “is very unusual for a system like this,” he said. “Early data suggests that use of the SAPIEN M3 System is feasible for treating patients with severe MR who are at high risk for mitral valve surgery and warrants further investigation,” Webb said.